AXT-1003 not checked
Axter Therapeutics (Beijing) Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.”In the company’s words, NCT06484985 on ClinicalTrials.gov
- Tested for
- Non-Hodgkin Lymphoma, Advanced Solid Tumor, mCRPC
- Main trialPhase 1
- “This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.”In the company’s words, NCT06484985 on ClinicalTrials.gov
Other drugs for Non-Hodgkin Lymphoma
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up2
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- Aug 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Mar 2027 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | |
| Phase 1Recruiting | Aug 2028 | AXT-1003 Combination With Enzalutamide in Participants With mCRPC | |
| Phase 1Terminated | 5 Sep 2023 | Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026